RecruitingNCT05576103

Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients

Longitudinal Prospective Study of Neurocognitive Outcomes and Multimodal Quantitative Neuroimaging Outcomes in Primary Brain Tumor Patients Receiving Brain Radiotherapy

Sponsor

Jona Hattangadi-Gluth

Enrollment

250 participants

Start Date

Jan 1, 2015

Study Type

OBSERVATIONAL

Conditions

Meningioma Glioma Primary Brain Tumor Schwannoma

Summary

In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through this study to improve understanding of cognitive changes associated with radiation dosage to non-targeted tissue, and will provide the basis for evidence-based cognitive- sparing brain radiotherapy.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This study is tracking changes in memory, thinking, and brain structure over time in people with primary brain tumors who are receiving radiation therapy. Researchers want to understand how radiation affects the brain and identify early warning signs of cognitive decline. **You may be eligible if...** - You are 18 or older - You have a primary brain tumor and are about to receive partial-brain radiation therapy - You have a life expectancy of at least 1 year - You are well enough to complete cognitive (thinking and memory) tests (Karnofsky score of 70 or higher) **You may NOT be eligible if...** - You cannot undergo an MRI with contrast dye - You have had prior radiation to the brain Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Moores Cancer Center

San Diego, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05576103

Related Trials

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT073265664 locations

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

NCT0563661819 locations

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

NCT074649253 locations

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

NCT055555501 location

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

NCT072106321 location